JP2772695B2 - 3-layer tablet - Google Patents
3-layer tabletInfo
- Publication number
- JP2772695B2 JP2772695B2 JP2016719A JP1671990A JP2772695B2 JP 2772695 B2 JP2772695 B2 JP 2772695B2 JP 2016719 A JP2016719 A JP 2016719A JP 1671990 A JP1671990 A JP 1671990A JP 2772695 B2 JP2772695 B2 JP 2772695B2
- Authority
- JP
- Japan
- Prior art keywords
- composition
- release
- drug
- sustained
- tablet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
- Y02A40/80—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in fisheries management
- Y02A40/81—Aquaculture, e.g. of fish
Landscapes
- Farming Of Fish And Shellfish (AREA)
- Medicinal Preparation (AREA)
Description
【発明の詳細な説明】 〔産業上の利用分野〕 本発明は血中濃度を維持することの必要な経口用医薬
又は一定の薬物濃度を維持することが必要な養魚場のい
けす等に投入される薬剤等に好適に用いることができ、
薬物放出速度をコントロールできる徐放性３層錠に関す
る。DETAILED DESCRIPTION OF THE INVENTION [Industrial Application Field] The present invention is applied to oral medicines that need to maintain blood concentrations or fish farms that need to maintain a constant drug concentration. Can be suitably used for drugs
The present invention relates to a sustained-release three-layer tablet capable of controlling a drug release rate.
従来のヒドロキシプロピルメチルセルロース、ヒドロ
キシプロピルセルロース等の水溶性高分子を用いたマト
リックス型の徐放性製剤は錠剤全体が均一な組成をし
ているモノリス型と錠剤の中心部に薬物を含むマトリ
ックスを含有し、その周囲を薬物を含まないマトリック
スに包まれているリザーバー型に大別される。これらの
いずれの形態も服用後、錠剤の外側から水和ゲルが形成
され、これが拡散層となり薬物を徐放している。Conventional matrix-type sustained-release preparations using water-soluble polymers such as hydroxypropylmethylcellulose and hydroxypropylcellulose contain a monolithic type in which the entire tablet has a uniform composition and a matrix containing the drug in the center of the tablet. The reservoir is roughly divided into a reservoir type that is surrounded by a drug-free matrix. After taking any of these forms, a hydrated gel is formed from the outside of the tablet, and this forms a diffusion layer to release the drug slowly.
しかしながらモノリス型の場合、水和ゲルの形成と薬
物の溶解が同時に進行するため放出を制御している水和
ゲルが充分に成形される前に薬物が放出されてしまう。
このため、放出曲線は上に凸の１次放出曲線となり、薬
物の放出安定性に問題があった。また腸管の運動の影響
を受けて必要以上に薬物が放出されるバースト現象が生
じやすいという欠点を有している。However, in the case of the monolith type, since the formation of the hydrated gel and the dissolution of the drug proceed simultaneously, the drug is released before the hydrated gel controlling the release is sufficiently formed.
For this reason, the release curve becomes a primary release curve that is convex upward, and there is a problem in the release stability of the drug. In addition, there is a disadvantage that a burst phenomenon in which a drug is released more than necessary under the influence of intestinal motility easily occurs.
一方リザーバー型は水和ゲルの充分な形成の後に薬物
を含有した核が溶け始めるために、放出曲線は下に凸の
近似的に０次の放出曲線を示す。また、構造上水和ゲル
が形成されるまでのタイムラグがあるために薬物の放出
が直ちに始まらないという欠点がある。On the other hand, in the case of the reservoir type, since the core containing the drug begins to dissolve after sufficient formation of the hydrated gel, the release curve shows an approximately zero-order release curve convex downward. Further, there is a drawback that the release of the drug does not immediately start due to a time lag until the hydrated gel is formed in terms of structure.
このように水溶性高分子を基材としたマトリックス型
徐放性製剤は薬物の徐放化という目的は達成している
が、有効血中濃度を維持するために要求される薬物放出
の安定性、初期の放出性という点で問題があった。従っ
て、初期放出性が充分であり、かつ放出性が安定に維持
できる徐放性製剤の開発が切望されていた。As described above, the matrix-type sustained-release preparation based on a water-soluble polymer achieves the purpose of sustained release of a drug, but the drug release stability required to maintain an effective blood concentration. However, there was a problem in terms of initial release. Therefore, development of a sustained-release preparation that has a sufficient initial release property and can maintain the release property stably has been desired.
本発明者らは上記実情に鑑み鋭意研究を行った結果、
マトリックス錠の形態を３層構造にし、中間層に薬物を
含有せしめた錠剤が上記課題を解決し、薬物放出速度を
コントロールできるものであることを見出し本発明を完
成した。The present inventors have conducted intensive research in view of the above circumstances,
The present inventors have found that a matrix tablet having a three-layer structure and containing a drug in an intermediate layer solves the above-mentioned problems and can control the drug release rate, and thus completed the present invention.
すなわち、本発明は、薬物を水溶性高分子の徐放性マ
トリックス中の含有せしめた層が、薬物を含まない上記
と同じ水溶性高分子を基材とする上下２層の間に挟装さ
れていることを特徴とする徐放性３層錠を提供するもの
である。That is, in the present invention, a layer containing a drug in a sustained-release matrix of a water-soluble polymer is sandwiched between two upper and lower layers based on the same water-soluble polymer containing no drug. It is intended to provide a sustained-release three-layer tablet characterized in that:
本発明に用いる水溶性高分子としては徐放性マトリッ
クスを形成するもの、例えばヒドロキシプロピルメチル
セルロース（HPMC）、ヒドロキシプロピルセルロース
（HPC）、メチルセルロース（MC）、ポビドン（PVP）、
ポリビニルアルコール（PVA）、ポリアクリロ酸ナトリ
ウム、カルボキシビニルポリマー、アルギン酸ナトリウ
ム、プルラン等が挙げられる。As the water-soluble polymer used in the present invention, those forming a sustained-release matrix, such as hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), methylcellulose (MC), povidone (PVP),
Examples include polyvinyl alcohol (PVA), sodium polyacrylate, carboxyvinyl polymer, sodium alginate, pullulan and the like.
本発明に用いる薬物は徐放性を期待するものであれば
特に制限はなく、具体例としては制酸剤（水酸化アルミ
ニウム、水酸化マグネシウム、シメチジン等）、抗ヒス
タミン剤（マレイン酸クロルフェニラミン、ジフェニル
ピラリン等）、消炎剤（インドメタシン、イブプロフェ
ン、プレドニゾロン等）、解熱剤（アセトアミノフェ
ン、アスピリン、メフェナム酸等）、喘息防止剤、咳止
め（リン酸ジヒドロコデイン、ノスカピン等）、高血圧
防止剤、抗生物質等が挙げられる。The drug used in the present invention is not particularly limited as long as it is expected to provide sustained release, and specific examples thereof include antacids (aluminum hydroxide, magnesium hydroxide, cimetidine, etc.), antihistamines (chlorpheniramine maleate, diphenyl Pyralin, etc.), anti-inflammatory agents (indomethacin, ibuprofen, prednisolone, etc.), antipyretics (acetaminophen, aspirin, mefenamic acid, etc.), antiasthmatics, cough (dihydrocodeine phosphate, noscapine, etc.), antihypertensives, antibiotics, etc. Is mentioned.
本発明３層錠の各層の成分には所望により錠剤に通常
用いられるもの、例えば滑沢剤、乳糖、結晶セルロース
及びリン酸水素カルシウム等の賦形剤、界面活性剤、色
素等を添加してもよい。The components of each layer of the three-layer tablet of the present invention may optionally contain components commonly used for tablets, such as lubricants, lactose, excipients such as crystalline cellulose and calcium hydrogen phosphate, surfactants, and pigments. Is also good.
本発明の３層錠を製造するには、例えば、薬物を含ま
ない水溶性高分子（組成Ａ）、薬物を含む水溶性高分子
（組成Ｂ）、薬物を含まない水溶性高分子（組成Ａ）の
順に各々の粉体を積層、圧縮すればよい。なお、各層の
成分は必要により予め乾式又は湿式の造粒を実施しても
よい。具体的な製造法としては、例えば第１図に示す如
く行えばよい。すなわち、まず組成Ａを打錠機の臼に入
れ（１）、上杵を下降させて軽く予圧縮を行う（２）。
次に上杵を上昇させ、組成Ａの層の上に組成Ｂを入れ
（３）、上杵を下降させて軽く予圧縮を行う（４）。上
杵を上昇させ更にこの２層の上に組成Ａを入れ（５）、
これを圧縮成形し（６）、これを取り出せば本発明の３
層錠が得られる（７）。To produce the three-layer tablet of the present invention, for example, a drug-free water-soluble polymer (composition A), a drug-containing water-soluble polymer (composition B), and a drug-free water-soluble polymer (composition A) ) May be laminated and compressed in this order. The components of each layer may be subjected to dry or wet granulation as necessary. A specific manufacturing method may be, for example, as shown in FIG. That is, first, the composition A is put into a die of a tableting machine (1), and the upper punch is lowered to perform light pre-compression (2).
Next, the upper punch is raised, and the composition B is put on the layer of the composition A (3), and the upper punch is lowered to perform light pre-compression (4). Raise the upper punch and further put composition A on these two layers (5),
This is compression-molded (6), and if it is taken out, it becomes 3 of the present invention.
A layer tablet is obtained (7).
本発明の徐放性３層錠は、初期放出性が良好であり、
かつその放出性が安定に維持される優れた除放性製剤で
ある。また、本発明の徐放性３層錠は組成Ａ及び組成Ｂ
の各々の量を変動させることにより、また粘度特性の異
なる種々の水溶性高分子を選択することにより、目的に
合わせて薬物放出速度をコントロールすることができる
有用な錠剤である。The sustained-release three-layer tablet of the present invention has a good initial release property,
And it is an excellent sustained-release preparation whose release property is stably maintained. In addition, the sustained-release three-layer tablet of the present invention comprises composition A and composition B.
Is a useful tablet whose drug release rate can be controlled according to the purpose by varying the amount of each of the above and by selecting various water-soluble polymers having different viscosity characteristics.
以下、実施例を挙げて本発明を更に詳細に説明する
が、本発明はこれらに限定されるものではない。Hereinafter, the present invention will be described in more detail with reference to Examples, but the present invention is not limited thereto.
実施例１ 次のＡ−からＡ−に示す如く、組成Ａの量を変化
させた錠剤を調製し、これらの薬物放出曲線を以下の方
法で求めた。結果を第２図に示す。Example 1 As shown in the following A- to A-, tablets in which the amount of the composition A was changed were prepared, and their drug release curves were determined by the following method. The results are shown in FIG.
Ａ− メトキシル基28.7％及びヒドロキシプロポキシル基9.
1％を含有する粘度4630csのヒドロキシプロピルメチル
セルロースを組成Ａとし、別に塩酸フェニルプロパノー
ルアミン20％、組成Ａと同じ仕様のヒドロキシプロピル
メチルセルロース80％を均一に混合したものを組成Ｂと
し、第１図に示す方法に従い初めに組成Ａを125mg、次
に組成Ｂを250mg、更に再び組成Ａを125mgそれぞれ積層
した後、200kg/cm2の圧力で圧縮成形し徐放性の錠剤を
調製した。A-Methoxyl group 28.7% and hydroxypropoxyl group 9.
The composition A was composed of hydroxypropyl methylcellulose having a viscosity of 4630 cs containing 1%, and the composition B was prepared by uniformly mixing 20% of phenylpropanolamine hydrochloride and 80% of hydroxypropylmethylcellulose having the same specifications as the composition A, as shown in FIG. According to the method shown, 125 mg of the composition A, 250 mg of the composition B, and 125 mg of the composition A were laminated, and then compression-molded at a pressure of 200 kg / cm 2 to prepare a sustained-release tablet.
Ａ− メトキシル基28.7％及びヒドロキシプロポキシル基9.
1％を含有する粘度4630csのヒドロキシプロピルメチル
セルロースを組成Ａとし、別に塩酸フェニルプロパノー
ルアミン20％、組成Ａと同じ仕様のヒドロキシプロピル
メチルセルロース80％を均一に混合したものを組成Ｂと
し、第１図に示す方法に従い初めに組成Ａを60mg、次に
組成Ｂを250mg、更に再び組成Ａを60mgそれぞれ積層し
た後、200kg/cm2の圧力で圧縮成形し徐放性の錠剤を調
製した。A-Methoxyl group 28.7% and hydroxypropoxyl group 9.
The composition A was composed of hydroxypropyl methylcellulose having a viscosity of 4630 cs containing 1%, and the composition B was prepared by uniformly mixing 20% of phenylpropanolamine hydrochloride and 80% of hydroxypropylmethylcellulose having the same specifications as the composition A, as shown in FIG. According to the method shown, 60 mg of the composition A, 250 mg of the composition B, and 60 mg of the composition A were laminated, and then compression-molded at a pressure of 200 kg / cm 2 to prepare a sustained-release tablet.
Ａ− メトキシル基28.7％及びヒドロキシプロポキシル基9.
1％を含有する粘度4630csのヒドロキシプロピルメチル
セルロースを組成Ａとし、別に塩酸フェニルプロパノー
ルアミン20％、組成Ａと同じ仕様のヒドロキシプロピル
メチルセルロース80％を均一に混合したものを組成Ｂと
し、第１図に示す方法に従い初めに組成Ａを200mg、次
に組成Ｂを250mg、更に再び組成Ａを200mgそれぞれ積層
した後、200kg/cm2の圧力で圧縮成形し徐放性の錠剤を
調製した。A-Methoxyl group 28.7% and hydroxypropoxyl group 9.
The composition A was composed of hydroxypropyl methylcellulose having a viscosity of 4630 cs containing 1%, and the composition B was prepared by uniformly mixing 20% of phenylpropanolamine hydrochloride and 80% of hydroxypropylmethylcellulose having the same specifications as the composition A, as shown in FIG. According to the method shown, 200 mg of the composition A, 250 mg of the composition B, and 200 mg of the composition A were laminated, and then compression-molded under a pressure of 200 kg / cm 2 to prepare a sustained-release tablet.
方法 実施例に示した方法により得た徐放性製剤について、
日本薬局方溶出試験法に準じ、下記の条件で溶出試験を
行った。Method For the sustained release formulation obtained by the method shown in the Examples,
According to the dissolution test method of the Japanese Pharmacopoeia, a dissolution test was performed under the following conditions.
溶 出 液：第１液500ml 温 度:37℃ 試 験 法：パドル法（100rpm） 徐放性製剤:1錠 塩酸フェニルプロパノールアミンの265nmの極大吸収
を吸光度測定することにより、任意時間における溶出量
を求める。これにより時間、溶出率曲線を作図し、薬物
放出曲線とした。Eluent: 500 ml of the first solution Temperature: 37 ° C Test method: Paddle method (100 rpm) Sustained-release preparation: 1 tablet The amount of elution at any time by measuring the maximum absorption at 265 nm of phenylpropanolamine hydrochloride by absorbance measurement Ask for. In this way, a time-elution rate curve was plotted and used as a drug release curve.
結果 第２図から明らかなように本発明の３層錠は、いずれ
も初期より良好な放出性を示し、その放出性を安定に維
持できた。また薬物を含まない水溶性高分子層の厚さを
変化させることにより、徐放性が容易にコントロールで
きた。Results As is evident from FIG. 2, all of the three-layer tablets of the present invention exhibited a better release than the initial stage, and the release was maintained stably. Also, by changing the thickness of the water-soluble polymer layer containing no drug, the sustained release could be easily controlled.
実施例２ 次のＢ〜Ｄに示す如く、種々の水溶性高分子を用いた
錠剤を調製し、これらの薬物放出曲線を実施例１と同様
な方法により求めた。結果を第３図に示す。Example 2 As shown in the following BD, tablets using various water-soluble polymers were prepared, and their drug release curves were determined in the same manner as in Example 1. The results are shown in FIG.
Ｂ ポビドンＫ−90に２％のステアリン酸マグネシウムを
加えたものを組成Ａとし、塩酸フェニルプロパノールア
ミン20％及び組成Ａと同じ仕様のポビドンＫ−90 80％
を均一に混合したものを組成Ｂとし、第１図に示す方法
に従い初めに組成Ａを125mg、次に組成Ｂを250mg、更に
再び組成Ａを125mgそれぞれ積層した後、200kg/cm2の圧
力で圧縮成形し徐放性の錠剤を調製した。B Povidone K-90 plus 2% magnesium stearate was used as composition A, phenylpropanolamine hydrochloride 20%, and povidone K-90 80% having the same specifications as composition A.
Is uniformly mixed to obtain a composition B. According to the method shown in FIG. 1, first, 125 mg of the composition A, 250 mg of the composition B, and 125 mg of the composition A are again laminated, and then, at a pressure of 200 kg / cm 2 . Compression molding was performed to prepare sustained-release tablets.
Ｃ ポリビニルアルコールに２％のステアリン酸マグネシ
ウムを加えたものを組成Ａとし、塩酸フェニルプロパノ
ールアミン20％及び組成Ａと同じ仕様のポリビニルアル
コール80％を均一に混合したものを組成Ｂとし第１図に
示す方法に従い初めに組成Ａを125mg、次に組成Ｂを250
mg、更に再び組成Ａを125mgそれぞれ積層した後、200kg
/cm2の圧力で圧縮成形し徐放性の錠剤を調製した。C Polyvinyl alcohol to which 2% magnesium stearate is added is referred to as composition A, and a composition obtained by uniformly mixing 20% of phenylpropanolamine hydrochloride and 80% of polyvinyl alcohol having the same specification as composition A is referred to as composition B, as shown in FIG. According to the method shown, first, the composition A was 125 mg, and then the composition B was 250 mg.
200 mg each after further laminating 125 mg each of composition A
The tablets were compression-molded at a pressure of / cm 2 to prepare sustained-release tablets.
Ｄ カルボキシビニルポリマーに２％のステアリン酸マグ
ネシウムを加えたものを組成Ａとし、塩酸フェニルプロ
パノールアミン20％及び組成Ａと同じ仕様のカルボキシ
ビニルポリマーアルコール80％を均一に混合したものを
組成Ｂとし、第１図に示す方法に従い初めに組成Ａを12
5mg、次に組成Ｂを250mg、更に再び組成Ａを125mgそれ
ぞれ積層した後、200kg/cm2の圧力で圧縮成形し徐放性
の錠剤を調製した。D A composition obtained by adding 2% of magnesium stearate to a carboxyvinyl polymer is referred to as a composition A, and a composition obtained by uniformly mixing 20% of phenylpropanolamine hydrochloride and 80% of a carboxyvinyl polymer alcohol having the same specifications as the composition A is referred to as a composition B. According to the method shown in FIG.
5 mg, then 250 mg of composition B, and 125 mg of composition A again were laminated, followed by compression molding at a pressure of 200 kg / cm 2 to prepare sustained-release tablets.
第１図は本発明の３層錠の製造例を示す図面であり、第
２図及び第３図は本発明の３層錠の薬物放出曲線を示す
図面である。FIG. 1 is a drawing showing a production example of the three-layer tablet of the present invention, and FIGS. 2 and 3 are drug release curves of the three-layer tablet of the present invention.
───────────────────────────────────────────────────── フロントページの続き (58)調査した分野(Int.Cl.6，ＤＢ名) A61K 9/20 - 9/24 A61K 47/30 - 47/38 A01K 61/00──────────────────────────────────────────────────続 き Continued on the front page (58) Field surveyed (Int.Cl. 6 , DB name) A61K 9/20-9/24 A61K 47/30-47/38 A01K 61/00
Claims (1)
中に含有せしめた層が、薬物を含まない上記と同じ水溶
性高分子を基材とする上下２層の間に挟装されているこ
とを特徴とする徐放性３層錠。1. A layer in which a drug is contained in a sustained-release matrix of a water-soluble polymer, which is sandwiched between two upper and lower layers based on the same water-soluble polymer containing no drug. Sustained-release three-layer tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016719A JP2772695B2 (en) | 1990-01-26 | 1990-01-26 | 3-layer tablet |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016719A JP2772695B2 (en) | 1990-01-26 | 1990-01-26 | 3-layer tablet |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH03223211A JPH03223211A (en) | 1991-10-02 |
| JP2772695B2 true JP2772695B2 (en) | 1998-07-02 |
Family
ID=11924075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016719A Expired - Lifetime JP2772695B2 (en) | 1990-01-26 | 1990-01-26 | 3-layer tablet |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2772695B2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7927624B2 (en) | 2000-04-14 | 2011-04-19 | Jagotec Ag | Hydrophilic/lipophilic polymeric matrix dosage formulation |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5651818B2 (en) | 2007-12-17 | 2015-01-14 | パラディン ラブス インコーポレーテッド | Controlled release formulation to prevent misuse |
| AU2009327312A1 (en) | 2008-12-16 | 2011-08-04 | Labopharm Europe Limited | Misuse preventative, controlled release formulation |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63301817A (en) * | 1987-05-30 | 1988-12-08 | Taisho Pharmaceut Co Ltd | Ibuprofen tablet |
-
1990
- 1990-01-26 JP JP2016719A patent/JP2772695B2/en not_active Expired - Lifetime
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7927624B2 (en) | 2000-04-14 | 2011-04-19 | Jagotec Ag | Hydrophilic/lipophilic polymeric matrix dosage formulation |
| US8303986B2 (en) | 2000-04-14 | 2012-11-06 | Jagotec Ag | Hydrophilic/lipophilic polymeric matrix dosage formulation |
| US8460706B2 (en) | 2000-04-14 | 2013-06-11 | Jagotec Ag | Hydrophilic/lipophilic polymeric matrix dosage formulation |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH03223211A (en) | 1991-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3251190B2 (en) | Pharmaceutical compressed tablets with high volume increase upon contact with body fluids | |
| US5085865A (en) | Sustained release pharmaceutical preparations containing an analgesic and a decongestant | |
| EP1416920B1 (en) | Multiplex drug delivery system suitable for oral administration | |
| AU736052B2 (en) | Pharmaceutical compositions for controlled release of active substances | |
| CA2096575C (en) | Novel simethicone containing pharmaceutical compositions | |
| US5451409A (en) | Sustained release matrix system using hydroxyethyl cellulose and hydroxypropyl cellulose polymer blends | |
| DE69318415T2 (en) | MEDICINAL TABLET ABLE TO RELEASE ONE OR MORE ACTIVE SUBSTANCES WITH DIFFERENT DISPOSAL RATES | |
| US6476006B2 (en) | Composition and dosage form for delayed gastric release of alendronate and/or other bis-phosphonates | |
| KR100364328B1 (en) | Tablet with controlled release of alfuzosine chlorydrate | |
| US6033685A (en) | Tablet for the controlled release of active agents | |
| US20110071137A1 (en) | Process for preparing sustained release tablets | |
| US20040052844A1 (en) | Time-controlled, sustained release, pharmaceutical composition containing water-soluble resins | |
| JPH11509829A (en) | Controlled release drug suspension delivery device | |
| JP2010518073A (en) | Oral sustained release trilayer tablet | |
| NZ239567A (en) | Sustained release pharmaceutical dosage form: capsule containing minitablets each containing an active agent in a sustained release xanthan gum matrix | |
| JP2772695B2 (en) | 3-layer tablet | |
| US20100305179A1 (en) | Oral sustained-release tablet | |
| JP2004002348A (en) | Miniaturized nifidipine nucleated tablet | |
| JPS60132915A (en) | Release controlled tablet for oral administration of ketoprofen and manufacture | |
| JPH11193230A (en) | Controlled-release preparation | |
| KR101696164B1 (en) | A method for the production of bioadhesive compact matrices | |
| US20180169021A1 (en) | Ranolazine multiple compressed tablets | |
| KR20210105761A (en) | A sustained release dosage form comprising choline alphoscerate as an active ingredient | |
| WO2024017411A1 (en) | Biphasic controlled-release formulation and preparation method therefor | |
| WO2018001582A1 (en) | Ranolazine multiple compressed tablets |